Dedicator of Cytokinesis Protein: A Potential Drug Target and Biomarker

Target Name: Dedicator of cytokinesis protein

NCBI ID: P44960

Dedicator of cytokinesis protein

Other Name(s): Dedicator of Cytokinesis | DOCK

Dedicator of Cytokinesis Protein: A Potential Drug Target and Biomarker

Introduction

Cytokinesis is a critical process that occurs in eukaryotic cells, where the cell physically separates into two daughter cells. The Dedicator of Cytokinesis Protein (DCP) is a protein that plays a crucial role in regulating cytokinesis. It is a non-specified subunit of the The tubulin family, located in the centriole and microtubule systems, is involved in spindles and cell division. Under normal circumstances, DCP inhibits the polymerization of spindle microtubules by binding to tubulin, thereby preventing spindles from emerging from centrioles and causing abnormal cell division. However, in some diseases, such as tumors and neurodegenerative diseases, DCP function is dysregulated. Therefore, studying the function and mechanism of DCP is of great significance for the development of drugs to treat these diseases.

Biological functions of DCP

DCP is a protein with a molecular weight of approximately 42 kDa. The expression levels of DCP vary in various cells. It is expressed in higher plants, fungi, and protozoa. The main function of DCP is to regulate the polymerization of spindle microtubules, thereby affecting cell mitosis.

DCP and mitosis

DCP plays an important role in mitosis. Mitosis is a form of cell division divided into prophase, metaphase and anaphase. During prophase of mitosis, DCP binds to spindle microtubules. During metaphase, DCP binds to proteins on spindle microtubules to form a stable complex. During anaphase of mitosis, DCP detaches from microtubules and the spindle begins to separate, leading to completion of cell division.

DCP and tumors

Tumor is a disease of abnormal cell proliferation, in which many tumor cells proliferate uncontrollably. The role of DCP in tumors has also attracted the attention of researchers. Studies have shown that the expression level of DCP is closely related to tumor aggressiveness and treatment response. In some tumors, the expression level of DCP is positively correlated with tumor prognosis. In addition, inhibition of DCP has also shown effects on tumor treatment. Therefore, targeting DCP can improve the efficacy of tumors and bring better treatment prospects to tumor patients.

DCP and neurodegenerative diseases

Neurodegenerative disease is a degenerative disease of the nervous system, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. These diseases cause neuronal damage and death, affecting patients' quality of life. The role of DCP in neurodegenerative diseases has also attracted the attention of researchers. Studies have shown that the expression level of DCP is closely related to the morbidity and mortality of neurodegenerative diseases. In some neurodegenerative diseases, the expression level of DCP is positively correlated with the severity of the disease. Therefore, by targeting DCP, the impact of neurodegenerative diseases can be alleviated and patients' quality of life improved.

Drug Screening for DCP

In order to study drug screening of DCP, researchers first need to identify the specific ligand of DCP. Specific ligands are molecules that bind to specific targets. By binding specific ligands, compounds with affinity can be screened. Currently, drug screening for DCP mainly includes the following two methods:

1. Immunochemical methods

Immunochemical methods are a widely used screening method, including antigen-antibody hybridization, Western Blot, and Western blotting. These methods can combine specific antigens or antibodies with specific ligands to achieve specific binding of DCP. Through this method, compounds with affinity can be screened to provide a basis for subsequent drug screening.

2. Cell-level methods

Cell-level methods include fluorescence microscopy, HCA assay, and flow cytometry. These methods can detect the expression level of DCP at the cellular level to screen out specific compounds. Through this method, specific compounds can be screened out to provide a basis for subsequent drug screening.

Bioinformatics analysis of DCP

Bioinformatics analysis is a new screening method that can process and analyze large amounts of data through computers to screen out specific compounds. Currently, commonly used bioinformatics analysis methods include bioinformatics databases, databases, and cloud computing platforms. Through these platforms, the gene expression, protein expression and function of DCP can be analyzed.

Protein Name: Dedicator Of Cytokinesis Protein (nonspecified Subtype)

The "Dedicator of cytokinesis protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Dedicator of cytokinesis protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets